person · Reporting owner
Fairmount Healthcare Fund L.P.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apogee Therapeutics, Inc.APGE · Entity 1939 | Director | March 28, 2024 | April 01, 2024 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Director · 10% owner | December 29, 2023 | December 29, 2023 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | March 28, 2024 | April 01, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apogee Therapeutics, Inc.
Report date March 28, 2024 · Filed April 01, 2024
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund LP | 0 |
Reported balance
After 2024-03-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-03-28 · Other · Disposed 55,913 · Balance 0 F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F2: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund II LP | 2,048,647 |
Reported balance
After 2024-03-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-03-28 · Other · Acquired 55,913 · Balance 2,048,647 F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F3: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Non-Voting Common StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund LP | 0 |
Reported balance
After 2024-03-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-28 · Other · Disposed 221,426 · Balance 0 F4: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%. F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F2: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Non-Voting Common StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund II LP | 6,743,321 |
Reported balance
After 2024-03-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-28 · Other · Acquired 221,426 · Balance 6,743,321 F4: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%. F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F3: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Tomas Kiselak | 51,166 |
Reported balance
Holding disclosure · report date 2024-03-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 51,166 |
| Common StockSEC Table I · non-derivative | IndirectBy Peter Harwin | 51,166 |
Reported balance
Holding disclosure · report date 2024-03-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 51,166 |
Filing footnotes · ownership attribution and instrument terms
F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").
F2: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F3: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F4: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.
Spyre Therapeutics, Inc.
Report date December 29, 2023 · Filed December 29, 2023
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest L.P., Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Co-Invest L.P. | 0 |
Reported balance
After 2023-12-29 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-12-29 · Other · Disposed 3,435,480 · Balance 0 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Tomas Kiselak | 406,038 |
Reported balance
After 2023-12-29 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-12-29 · Other · Acquired 406,038 · Balance 406,038 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. |
| Common StockSEC Table I · non-derivative | IndirectBy Peter Harwin | 406,038 |
Reported balance
After 2023-12-29 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2023-12-29 · Other · Acquired 406,038 · Balance 406,038 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. |
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund II L.P. | 378,421 |
Reported balance
Holding disclosure · report date 2023-12-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 378,421 F3: On December 29, 2023, the shares of Common Stock and Series A non-voting convertible preferred stock (the "Series A Preferred Stock") held by Fund I were transferred to Fund II. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund II L.P. | 437,037 |
Reported balance
Holding disclosure · report date 2023-12-29 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 437,037 F4: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3: On December 29, 2023, the shares of Common Stock and Series A non-voting convertible preferred stock (the "Series A Preferred Stock") held by Fund I were transferred to Fund II. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund II L.P. | 16,667 |
Reported balance
Holding disclosure · report date 2023-12-29 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 16,667 F5: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.
F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3: On December 29, 2023, the shares of Common Stock and Series A non-voting convertible preferred stock (the "Series A Preferred Stock") held by Fund I were transferred to Fund II.
F4: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.
F5: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.
Viridian Therapeutics, Inc.\DE
Report date March 28, 2024 · Filed April 01, 2024
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Fairmount Healthcare Fund II GP LLC, Fairmount Healthcare Fund II L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectFairmount Healthcare Fund LP | 0 |
Reported balance
After 2024-03-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-03-28 · Other · Disposed 5,859 · Balance 0 F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F2: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectFairmount Healthcare Fund II LP | 1,845,813 |
Reported balance
After 2024-03-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-03-28 · Other · Acquired 5,859 · Balance 1,845,813 F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F3: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Series A Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund LP | 0 |
Reported balance
After 2024-03-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-28 · Other · Disposed 21,999 · Balance 0 F4: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F2: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Series A Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund II LP | 133,191 |
Reported balance
After 2024-03-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-28 · Other · Acquired 21,999 · Balance 133,191 F4: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F3: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").
F2: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F3: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F4: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2024 Filed Apr 1, 2024 17:44 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | OtherNon-Voting Common Stock · Derivative | 221,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · derivative · entry 6 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II LP Disclosed balance after: 6,743,321 Underlying: Common Stock · 6,521,895 shares Expires not disclosed F4 · derivative.exercise_price: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%. F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F4 · derivative.exercise_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%. F4 · derivative.expiration_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%. F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 17:44 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | OtherNon-Voting Common Stock · Derivative | 221,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · derivative · entry 5 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund LP Disclosed balance after: 0 Underlying: Common Stock · 221,426 shares Expires not disclosed F4 · derivative.exercise_price: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%. F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F4 · derivative.exercise_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%. F4 · derivative.expiration_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%. F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 17:44 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | OtherCommon Stock | 55,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II LP Disclosed balance after: 2,048,647 F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 17:44 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | OtherCommon Stock | 55,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund LP Disclosed balance after: 0 F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 21,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039599 · ownership.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II LP Disclosed balance after: 133,191 Underlying: Common Stock · 1,466,673 shares Expires not disclosed F4 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F4 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F4 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 21,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039599 · ownership.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund LP Disclosed balance after: 0 Underlying: Common Stock · 1,466,673 shares Expires not disclosed F4 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F4 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F4 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | OtherCommon Stock | 5,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-039599 · ownership.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 1,845,813 F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | OtherCommon Stock | 5,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-039599 · ownership.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 0 F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:31 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | OtherCommon Stock | 51,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-008835 · tm244753-2_4seq1.xml · nonDerivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Peter Harwin Disclosed balance after: 51,166 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:31 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | OtherCommon Stock | 51,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-008835 · tm244753-2_4seq1.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Tomas Kiselak Disclosed balance after: 51,166 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:31 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | OtherCommon Stock | 892,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-008835 · tm244753-2_4seq1.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Fairmount Healthcare Co-Invest II LP Disclosed balance after: 0 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 18:44 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | PurchaseCommon Stock | 476,190 | $21.00 | $9,999,990.00 |
DisclosureSEC source: 0000950170-24-007123 · ownership.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 1,839,954 F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 17:00 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | OtherCommon Stock | 406,038 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-073904 · ownership.xml · nonDerivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Peter Harwin Disclosed balance after: 406,038 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 17:00 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | OtherCommon Stock | 406,038 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-073904 · ownership.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Tomas Kiselak Disclosed balance after: 406,038 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 17:00 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | OtherCommon Stock | 3,435,480 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-073904 · ownership.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Fairmount Healthcare Co-Invest L.P. Disclosed balance after: 0 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 17:41 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantSeries B Preferred Stock · Derivative | 16,667 | $600.00 | $10,000,200.00 |
DisclosureSEC source: 0000950170-23-069455 · ownership.xml · derivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II L.P. Disclosed balance after: 16,667 Underlying: Common Stock · 666,680 shares Expires not disclosed F1 · derivative.exercise_price: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2 · shares: The shares of Series B Preferred Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended. F1 · derivative.exercise_date: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · derivative.expiration_date: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 24, 2023 Filed Nov 28, 2023 16:05 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | ConversionSeries A Preferred Stock · Derivative | 85,887 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-066399 · ownership.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Co-Invest L.P. Disclosed balance after: 0 Underlying: Common Stock · 3,435,480 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations. F1 · derivative.exercise_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations. F1 · derivative.expiration_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations. F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 24, 2023 Filed Nov 28, 2023 16:05 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | ConversionCommon Stock | 3,435,480 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-066399 · ownership.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Co-Invest L.P. Disclosed balance after: 3,435,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations. F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 21:05 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantSeries B Non-Voting Convertible Preferred Stock · Derivative | 48,463 | $825.37 | $40,000,129.24 |
DisclosureSEC source: 0000950170-23-057692 · ownership.xml · derivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II LP Disclosed balance after: 48,463 Underlying: Common Stock · 3,231,028.21 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F2 · shares: The shares of Series B non-voting convertible preferred stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended. F1 · derivative.exercise_date: Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1 · derivative.expiration_date: Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and Series B non-voting convertible preferred stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 20:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 47,758 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-23-081729 · tm2321456-6_4seq1.xml · derivative · entry 5 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,758 Underlying: Common Stock · 47,758 shares Expires 2033-07-13 F2 · derivative.exercise_date: This option represents the right to purchase 47,758 shares of the Issuer's common stock, and will vest in three approximately equal annual installments beginning on the first anniversary of the grant date. F4 · ownership.direct: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more Fairmount Funds. Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 20:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 47,758 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-23-081729 · tm2321456-6_4seq1.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,758 Underlying: Common Stock · 47,758 shares Expires 2033-07-13 F2 · derivative.exercise_date: This option represents the right to purchase 47,758 shares of the Issuer's common stock, and will vest in three approximately equal annual installments beginning on the first anniversary of the grant date. F3 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 20:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | PurchaseCommon Stock | 892,529 | $17.00 | $15,172,993.00 |
DisclosureSEC source: 0001104659-23-081729 · tm2321456-6_4seq1.xml · nonDerivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Co-Invest II LP Disclosed balance after: 892,529 F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest II LP. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 20:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | PurchaseCommon Stock | 1,992,734 | $17.00 | $33,876,478.00 |
DisclosureSEC source: 0001104659-23-081729 · tm2321456-6_4seq1.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II LP Disclosed balance after: 1,992,734 F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest II LP. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 20:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | PurchaseCommon Stock | 55,913 | $17.00 | $950,521.00 |
DisclosureSEC source: 0001104659-23-081729 · tm2321456-6_4seq1.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund LP Disclosed balance after: 55,913 F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest II LP. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | PurchaseCommon Stock | 425,531 | $23.50 | $9,999,978.50 |
DisclosureSEC source: 0001104659-22-092992 · tm2224209-1_4seq1.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · 10% owner Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 1,363,764 F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 09:30 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | PurchaseCommon Stock | 909,000 | $11.00 | $9,999,000.00 |
DisclosureSEC source: 0000899243-21-037255 · doc4.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 938,233 F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 11:53 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative | 28,843 | $465.96 | $13,439,684.28 |
DisclosureSEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 111,192 Underlying: Common Stock · 28,483,000 shares Expires not disclosed F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 11:53 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative | 5,494 | $465.96 | $2,559,984.24 |
DisclosureSEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 21,999 Underlying: Common Stock · 5,494,000 shares Expires not disclosed F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund LP ("Fund I"). They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 82,349 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 82,349 Underlying: Common Stock · 82,349,000 shares Expires not disclosed F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 16,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 16,505 Underlying: Common Stock · 16,505,000 shares Expires not disclosed F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherCommon Stock | 438,502 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 438,502 F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherCommon Stock | 87,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 87,891 F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.